5 Analysts Have This to Say About Oncolytics Biotech
Portfolio Pulse from Benzinga Insights
Five analysts have given bullish ratings for Oncolytics Biotech (NASDAQ:ONCY) in the last quarter, with an average price target of $11.8, implying significant upside from the current price of $2.66. This average price target has decreased by 21.33% from the previous average of $15.00.
June 29, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have given bullish ratings for Oncolytics Biotech, indicating potential upside.
The bullish ratings from five analysts indicate a positive outlook for Oncolytics Biotech. The average price target of $11.8 suggests a significant upside from the current price of $2.66. However, the decrease in the average price target from $15.00 to $11.8 may indicate some caution.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100